Acute Myeloid Leukaemia B003
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/sops-grouped-icd-body-system/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9
Rulebase for acute myeloid leukaemia
<h5>Current RMA Instruments:</h5><table border="1" cellpadding="1" cellspacing="1"><tbody><tr><td><address><a href="http://www.rma.gov.au/assets/SOP/2024/a87c4e8224/021.pdf" target="_blank"><u><font color="#0066cc">Reasonable Hypothesis SOP</font></u></a></address></td><td>21 of 2024 as amended </td></tr><tr><td><address><a href="http://www.rma.gov.au/assets/SOP/2024/a111ec6770/022.pdf" target="_blank"><u><font color="#0066cc">Balance of Probabilities SOP</font></u></a></address></td><td>22 of 2024 as amended </td></tr></tbody></table><h5>Changes from previous Instruments:</h5><p><drupal-media data-entity-type="media" data-entity-uuid="48af5fb9-15d5-48f0-ae35-23d8ee763a18" data-view-mode="wysiwyg"></drupal-media></p><h5>ICD Coding</h5><ul><li>ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01</li></ul><h5><strong>Brief description</strong></h5><p>Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from. </p><h5><strong>Confirming the diagnosis</strong></h5><p>Diagnosis usually requires bone marrow biopsy.</p><p>The relevant medical specialist is haematologist or a haematologist oncologist.</p><h5><strong>Additional diagnoses covered by these SOPs:</strong></h5><ul><li>Acute basophilic leukaemia</li><li>Acute erythroid leukaemia</li><li>Acute granulocytic leukaemia</li><li>Acute megakaryoblastic leukaemia</li><li>Acute monoblastic/monocytic leukaemia</li><li>Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)</li><li>Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities</li><li>Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation </li><li>Acute myeloid leukaemia, not otherwise specified</li><li>Acute myeloblastic leukaemia</li><li>Acute myelocytic leukaemia</li><li>Acute myelogenous leukaemia</li><li>Acute myelomonocytic leukaemia</li><li>Acute myelosclerotic leukaemia</li><li>Acute panmyelosis with myelofibrosis</li><li>Acute promyelocytic leukaemia</li><li>Erytholeukaemia</li><li>Myeloid sarcoma</li></ul><h5><strong>Conditions not covered by these SOPs</strong></h5><ul><li><span>Acute lymphoblastic leukaemia *</span></li><li>Chronic lymphocytic leukaemia/small lymphocytic lymphoma *</li><li>Chronic myeloid leukaemia *</li><li>Myeloma *</li><li>Myelodysplastic syndrome *</li><li>Soft tissue sarcoma *</li></ul><p>* another SOP applies - the SOP has the same name unless otherwise specified</p><p><sup>#</sup> non-SOP condition</p><h5><strong>Clinical onset</strong></h5><p>Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.</p><h5><strong>Clinical worsening</strong></h5><p>AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental. </p><h5><strong>Comments on SOP factors </strong></h5><p>Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.</p><p> </p>
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia
Atomic radiation
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/atomic-radiation
Being exposed to benzene
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/being-exposed-benzene
Being obese
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/being-obese
Chemotherapy
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/chemotherapy
Cigar smoking
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/cigar-smoking
Cigarette smoking
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/cigarette-smoking
Cumulative exposure to benzene
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/cumulative-exposure-benzene
Exposure to AVGAS or petroleum products containing benzene
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/exposure-avgas-or-petroleum-products-containing-benzene
Inability to obtain appropriate clinical management for acute myeloid leukaemia
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/inability-obtain-appropriate-clinical-management-acute-myeloid-leukaemia
Myelodysplastic disorder
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/myelodysplastic-disorder
Pipe smoking
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/pipe-smoking
Smoking tobacco products - material contribution
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/smoking-tobacco-products-material-contribution
Therapeutic radiation
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/therapeutic-radiation
Thorium dioxide (Thorotrast)
Current RMA Instruments:
| Reasonable Hypothesis SOP | 21 of 2024 as amended |
| Balance of Probabilities SOP | 22 of 2024 as amended |
Changes from previous Instruments:
ICD Coding
- ICD-10-AM Codes: C92.00-01, C92.30-31, C93.00-01, C94.00-01, C94.20-21, C95.00-01
Brief description
Acute myeloid leukaemia (AML) is a type of cancer that affects the blood and bone marrow. It involves rapid growth of abnormal white blood cells that accumulate in the bone marrow, the blood and other tissues. There is disruption of production of normal blood cells. 'Myeloid' refers to the type of cell the leukaemia starts from.
Confirming the diagnosis
Diagnosis usually requires bone marrow biopsy.
The relevant medical specialist is haematologist or a haematologist oncologist.
Additional diagnoses covered by these SOPs:
- Acute basophilic leukaemia
- Acute erythroid leukaemia
- Acute granulocytic leukaemia
- Acute megakaryoblastic leukaemia
- Acute monoblastic/monocytic leukaemia
- Acute myeloid leukaemia with defining genetic abnormalities (e.g. NPM1 mutation)
- Acute myeloid leukaemia, myelodysplasia-related genetic abnormalities
- Acute myeloid leukaemia with minimal differentiation, or without maturation or with maturation
- Acute myeloid leukaemia, not otherwise specified
- Acute myeloblastic leukaemia
- Acute myelocytic leukaemia
- Acute myelogenous leukaemia
- Acute myelomonocytic leukaemia
- Acute myelosclerotic leukaemia
- Acute panmyelosis with myelofibrosis
- Acute promyelocytic leukaemia
- Erytholeukaemia
- Myeloid sarcoma
Conditions not covered by these SOPs
- Acute lymphoblastic leukaemia *
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma *
- Chronic myeloid leukaemia *
- Myeloma *
- Myelodysplastic syndrome *
- Soft tissue sarcoma *
* another SOP applies - the SOP has the same name unless otherwise specified
# non-SOP condition
Clinical onset
Clinical onset will most likely be at the time of diagnosis. Early symtpoms are generally vague and non-specific. A slight back-dating of onset may be possible if symptoms of anaemia or of easy bruising/bleeding were present.
Clinical worsening
AML is a rapidly progressing disease and is typically fatal within weeks or months if left untreated. The only SoP worsening factor is for inability to obtain appropriate clincial management. Treatment may be curative (particularly in younger subjects) and will generally prolong survival. Any delay in treatment is likely to be detrimental.
Comments on SOP factors
Undergoing treatment with radioactive iodine or phosphorus does not include diagnostic procedures where these agents as used as tracers.
Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-myeloid-leukaemia-b003-c9200-01c9230-31c9/rulebase-acute-myeloid-leukaemia/thorium-dioxide-thorotrast